Lumretuzumab

Drug Profile

Lumretuzumab

Alternative Names: anti-HER3 monoclonal antibody - Roche; GE-HuMAb-HER3; HER3 MAb solid tumours - Roche; RG-7116; RO-5479599

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 07 Oct 2016 Safety and efficacy data from a phase I trial in Solid tumours presented at the 41st European Society of Medical Oncology Congress (ESMO-2016)
  • 01 Oct 2016 Roche completes a phase I trial in Breast cancer (Combination therapy, Metastatic disease) in Denmark, France, Germany and Spain (IV) (NCT01918254)
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top